Illumina taps IBM Watson for cancer data interpretation

IBM Watson Health is now collaborating with Illumina, a biotechnology company focused on genome sequencing solutions.

Through this partnership, Illumina will integrate Watson for Genomics into its BaseSpace Sequence Hub and tumor sequencing process in an effort to standardize genomic data interpretation. Watson for Genomics will read genetic alteration files alongside professional guidelines, medical literature and clinical trials to produce a comprehensive report for researchers.

The Watson for Genomics and Illumina integration will take place in early 2017.

More articles on health IT:
US IoT Working Group: IoT personalizes care, reduces cost in healthcare
University of Dayton to establish center for 'cyberhealth'
American Association for Cancer Research releases public cancer dataset with 19k records

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months